Major Patent Cliff Closes in on Big Pharma, Bargain-Priced Acquisitions Could Bolster Their Pipelines
![](https://www.mcalindenresearchpartners.com/wp-content/uploads/2022/07/pexels-polina-tankilevitch-3735781-1024x683.jpg)
Last year marked one of the least active years for biopharma merger and acquisition (M&A) activity in a decade. The first…
McAlinden Research PartnersJuly 14, 2022